Vulnerability and Therapeutic Changes in Older Patients With Multiple Myeloma.
Conditions
Multiple Myeloma in Older Patients
Conditions: official terms
Multiple Myeloma - Neoplasms, Plasma Cell
Conditions: Keywords
Multiple myeloma,, Older patient,, Treatment,, Geriatric assessment
Study Type
Interventional
Study Phase
N/A
Study Design
Intervention Model: Single Group Assignment, Masking: Open Label
Intervention
Name: Vulnerability and therapeutic changes in older patients with multiple myeloma.
Type: Other
Overall Status
Not yet recruiting
Summary
The aim of this study is to determine whether the presence of vulnerability detected by geriatricians is associated with treatment discontinuation in older patient. During the comprehensive geriatric assessment realized before the decision-treatment, the following data are recorded and their impact in the therapeutic changes will also be analysed: comorbidity, age, depression, functional status, the cognitive impairment and malnutrition.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 70 Years
Gender: Both
Criteria: Inclusion Criteria:

- Patients aged 70 years and older

- Patients referred for a assessment of a newly diagnosed multiple myeloma

- Patients for who the initial therapy proposed is either melphalan-prednisone-thalidomide or melphalan-prednisone-bortezomib or included in a phase 3 trial.

- Patients who provide informed written consent

Exclusion Criteria:

- Patients who refuse the study

- Patients who won't have therapy

- Patients can't respond to geriatric assessment because of severe cognitive disorder

- Patients with a legal guardian
Location
CHU de Nantes
Nantes, France
Status: Not yet recruiting
Contact: Laure De Decker, Dr - laure.dedecker@chu-nantes.fr
Start Date
April 2014
Completion Date
April 2017
Sponsors
Nantes University Hospital
Source
Nantes University Hospital
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page